Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avalo Therapeutics, Inc.
Report date July 16, 2019 · Filed April 17, 2020
Section 16 reporting ended · disclosed 2020-04-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,216 |
Reported balance
After 2019-07-16 transaction · row 1
1 source rowRow 1 · 2019-07-16 · Tax withholding · Disposed 3,246 · Balance 49,216 F1: Represents shares forfeited to the Issuer in connection with the satisfaction of tax liabilities incurred upon the vesting of restricted stock granted May 24, 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.26 · Expires 2028-07-16 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2019-07-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 80,000 F2: One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.22 · Expires 2029-04-01 | Direct | 175,000 |
Reported balance
Holding disclosure · report date 2019-07-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 175,000 F2: One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.98 · Expires 2029-05-24 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2019-07-16 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 25,000 F3: One-fourth of the shares subject to the stock option will vest on July 16, 2019, and the remaining three-fourths of the shares subject to the stock option will vest in substantially equal monthly installments over the following 36 months, provided the Reporting Person is then still providing continuous service as an employee, director or consultant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares forfeited to the Issuer in connection with the satisfaction of tax liabilities incurred upon the vesting of restricted stock granted May 24, 2019.
F2: One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months.
F3: One-fourth of the shares subject to the stock option will vest on July 16, 2019, and the remaining three-fourths of the shares subject to the stock option will vest in substantially equal monthly installments over the following 36 months, provided the Reporting Person is then still providing continuous service as an employee, director or consultant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2019 Filed Dec 11, 2019 21:15 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 2,913 | $2.85 | $8,294.77 |
DisclosureSEC source: 0001578563-19-000037 · primary_doc.xml · nonDerivative · entry 1 Calias Pericles · CIK 0001746282 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,462 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| July 16, 2019 Filed Apr 17, 2020 20:52 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | Tax withholdingCommon Stock | 3,246 | $4.90 | $15,905.40 |
DisclosureSEC source: 0001578563-20-000019 · primary_doc.xml · nonDerivative · entry 1 Calias Pericles · CIK 0001746282 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,216 F1 · shares: Represents shares forfeited to the Issuer in connection with the satisfaction of tax liabilities incurred upon the vesting of restricted stock granted May 24, 2019. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 23:36 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 4,549 | $2.85 | $12,953.28 |
DisclosureSEC source: 0001578563-19-000020 · primary_doc.xml · nonDerivative · entry 1 Calias Pericles · CIK 0001746282 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,549 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| May 24, 2019 Filed May 29, 2019 21:03 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001578563-19-000018 · primary_doc.xml · derivative · entry 2 Calias Pericles · CIK 0001746282 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-24 F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option will vest on July 16, 2019, and the remaining three-fourths of the shares subject to the stock option will vest in substantially equal monthly installments over the following 36 months, provided the Reporting Person is then still providing continuous service as an employee, director or consultant. Read SEC document |
| May 24, 2019 Filed May 29, 2019 21:03 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-19-000018 · primary_doc.xml · nonDerivative · entry 1 Calias Pericles · CIK 0001746282 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · shares: The restricted stock units vest in four equal installments beginning on July 16, 2019, provided the Reporting Person is then still providing continuous service as an employee, director or consultant. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 23:07 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001578563-19-000010 · primary_doc.xml · derivative · entry 1 Calias Pericles · CIK 0001746282 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2029-04-01 F1 · derivative.exercise_date: One fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months. Read SEC document |
| July 16, 2018 Filed Jul 16, 2018 20:56 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001746282-18-000003 · primary_doc.xml · derivative · entry 1 Calias Pericles · CIK 0001746282 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2028-07-15 F1 · derivative.exercise_date: The stock options will vest 25% on July 16, 2019, and the remaining 75% of the shares subject to the stock option shall vest in 36 equal monthly installments beginning on August 16, 2019, provided the Reporting Person is then an officer of the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.